Joshua Barocas
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Opioid-Related Disorders | 31 | 2025 | 482 | 9.460 |
Why?
| Drug Overdose | 22 | 2025 | 321 | 6.210 |
Why?
| Substance Abuse, Intravenous | 13 | 2025 | 108 | 5.840 |
Why?
| Hepatitis C | 10 | 2022 | 237 | 3.860 |
Why?
| Endocarditis | 7 | 2025 | 36 | 3.450 |
Why?
| Buprenorphine | 9 | 2024 | 160 | 2.780 |
Why?
| Substance-Related Disorders | 11 | 2024 | 1010 | 2.690 |
Why?
| Analgesics, Opioid | 21 | 2024 | 889 | 2.420 |
Why?
| Pharmaceutical Preparations | 6 | 2021 | 168 | 2.300 |
Why?
| Naloxone | 4 | 2024 | 111 | 2.170 |
Why?
| Epidemics | 4 | 2024 | 82 | 2.110 |
Why?
| Central Nervous System Stimulants | 3 | 2024 | 153 | 2.090 |
Why?
| Hepatitis C, Chronic | 4 | 2021 | 153 | 2.050 |
Why?
| HIV Infections | 12 | 2024 | 2711 | 1.930 |
Why?
| Endocarditis, Bacterial | 4 | 2023 | 42 | 1.870 |
Why?
| Amphetamine-Related Disorders | 2 | 2024 | 36 | 1.800 |
Why?
| Hepacivirus | 8 | 2022 | 235 | 1.760 |
Why?
| Massachusetts | 12 | 2025 | 158 | 1.720 |
Why?
| Narcotic Antagonists | 6 | 2024 | 161 | 1.680 |
Why?
| Drug Users | 4 | 2024 | 41 | 1.570 |
Why?
| Prisoners | 3 | 2024 | 141 | 1.470 |
Why?
| Cost-Benefit Analysis | 10 | 2023 | 569 | 1.380 |
Why?
| Soft Tissue Infections | 2 | 2021 | 35 | 1.380 |
Why?
| Buprenorphine, Naloxone Drug Combination | 3 | 2022 | 9 | 1.310 |
Why?
| Humans | 93 | 2025 | 128495 | 1.270 |
Why?
| Harm Reduction | 4 | 2024 | 31 | 1.250 |
Why?
| Anti-Infective Agents | 2 | 2022 | 245 | 1.200 |
Why?
| Hospitalization | 8 | 2024 | 2069 | 1.160 |
Why?
| Pneumonia, Viral | 3 | 2020 | 337 | 1.100 |
Why?
| Opiate Substitution Treatment | 6 | 2024 | 135 | 1.100 |
Why?
| Coronavirus Infections | 3 | 2020 | 333 | 1.100 |
Why?
| Prevalence | 13 | 2025 | 2553 | 1.060 |
Why?
| Housing | 3 | 2023 | 130 | 1.030 |
Why?
| Fentanyl | 3 | 2024 | 76 | 1.030 |
Why?
| Homeless Youth | 1 | 2025 | 18 | 0.940 |
Why?
| Mobile Health Units | 1 | 2024 | 19 | 0.920 |
Why?
| Epidemiological Monitoring | 1 | 2024 | 50 | 0.910 |
Why?
| Crime | 1 | 2024 | 56 | 0.910 |
Why?
| Patient Isolation | 2 | 2021 | 16 | 0.910 |
Why?
| Adult | 34 | 2025 | 35299 | 0.890 |
Why?
| Decision Trees | 1 | 2024 | 90 | 0.890 |
Why?
| Methamphetamine | 1 | 2024 | 54 | 0.870 |
Why?
| United States | 20 | 2025 | 13840 | 0.860 |
Why?
| Referral and Consultation | 3 | 2022 | 728 | 0.860 |
Why?
| Substance Abuse Treatment Centers | 2 | 2020 | 40 | 0.850 |
Why?
| Male | 41 | 2025 | 63043 | 0.850 |
Why?
| Antiviral Agents | 5 | 2022 | 711 | 0.830 |
Why?
| Young Adult | 17 | 2025 | 12349 | 0.810 |
Why?
| Health Personnel | 2 | 2020 | 649 | 0.800 |
Why?
| Mass Screening | 6 | 2020 | 1146 | 0.770 |
Why?
| Preventive Health Services | 2 | 2020 | 145 | 0.770 |
Why?
| Hospital Administration | 1 | 2021 | 21 | 0.760 |
Why?
| Crisis Intervention | 1 | 2021 | 33 | 0.750 |
Why?
| Female | 39 | 2025 | 68266 | 0.750 |
Why?
| Criminal Law | 1 | 2021 | 30 | 0.730 |
Why?
| Convalescence | 1 | 2021 | 18 | 0.720 |
Why?
| Hospital Units | 1 | 2021 | 24 | 0.720 |
Why?
| Liver Cirrhosis | 2 | 2022 | 279 | 0.710 |
Why?
| Public Health | 3 | 2023 | 482 | 0.710 |
Why?
| Health Communication | 1 | 2021 | 40 | 0.710 |
Why?
| Communicable Diseases | 2 | 2021 | 145 | 0.700 |
Why?
| Catheterization, Peripheral | 1 | 2022 | 104 | 0.700 |
Why?
| Residential Treatment | 1 | 2020 | 30 | 0.700 |
Why?
| Self Report | 1 | 2024 | 797 | 0.650 |
Why?
| Mental Disorders | 3 | 2024 | 1007 | 0.650 |
Why?
| Pre-Exposure Prophylaxis | 1 | 2022 | 203 | 0.650 |
Why?
| Safety-net Providers | 1 | 2021 | 109 | 0.650 |
Why?
| Middle Aged | 22 | 2025 | 30921 | 0.620 |
Why?
| Immunization Programs | 1 | 2020 | 213 | 0.610 |
Why?
| Needle-Exchange Programs | 2 | 2015 | 7 | 0.600 |
Why?
| Socioeconomic Factors | 2 | 2020 | 1212 | 0.590 |
Why?
| Research Design | 2 | 2023 | 1036 | 0.580 |
Why?
| Delivery of Health Care | 3 | 2024 | 889 | 0.580 |
Why?
| Adolescent | 15 | 2025 | 20304 | 0.560 |
Why?
| Sustained Virologic Response | 1 | 2017 | 37 | 0.550 |
Why?
| Diagnostic Tests, Routine | 1 | 2018 | 102 | 0.550 |
Why?
| Decision Support Techniques | 1 | 2021 | 396 | 0.540 |
Why?
| Delivery of Health Care, Integrated | 1 | 2019 | 240 | 0.520 |
Why?
| Patient Discharge | 2 | 2022 | 854 | 0.510 |
Why?
| Zinc | 1 | 2019 | 292 | 0.510 |
Why?
| Outpatients | 2 | 2020 | 368 | 0.500 |
Why?
| Pandemics | 8 | 2022 | 1477 | 0.500 |
Why?
| Emergency Medical Services | 1 | 2022 | 519 | 0.500 |
Why?
| Social Determinants of Health | 1 | 2019 | 221 | 0.500 |
Why?
| Guidelines as Topic | 1 | 2017 | 260 | 0.500 |
Why?
| Retrospective Studies | 10 | 2024 | 14471 | 0.490 |
Why?
| Anti-HIV Agents | 1 | 2022 | 751 | 0.490 |
Why?
| Monte Carlo Method | 3 | 2021 | 140 | 0.490 |
Why?
| Criminals | 1 | 2015 | 36 | 0.470 |
Why?
| Education | 1 | 2015 | 100 | 0.470 |
Why?
| Blastomyces | 1 | 2014 | 9 | 0.450 |
Why?
| Blastomycosis | 1 | 2014 | 10 | 0.450 |
Why?
| Boston | 4 | 2021 | 86 | 0.440 |
Why?
| HIV Seropositivity | 1 | 2014 | 119 | 0.440 |
Why?
| Advance Directives | 1 | 2014 | 77 | 0.440 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2022 | 821 | 0.430 |
Why?
| Peritonitis | 1 | 2014 | 81 | 0.430 |
Why?
| Naltrexone | 3 | 2024 | 84 | 0.400 |
Why?
| Alcohol Drinking | 1 | 2019 | 758 | 0.400 |
Why?
| Cohort Studies | 5 | 2024 | 5402 | 0.370 |
Why?
| Quarantine | 2 | 2021 | 27 | 0.350 |
Why?
| Injections | 2 | 2021 | 173 | 0.350 |
Why?
| Colorado | 3 | 2025 | 4399 | 0.340 |
Why?
| Vulnerable Populations | 2 | 2021 | 157 | 0.330 |
Why?
| Ohio | 3 | 2025 | 153 | 0.300 |
Why?
| Risk-Taking | 2 | 2021 | 347 | 0.300 |
Why?
| Cross-Sectional Studies | 5 | 2024 | 5045 | 0.290 |
Why?
| Kidney Transplantation | 1 | 2014 | 603 | 0.290 |
Why?
| Coinfection | 2 | 2019 | 131 | 0.290 |
Why?
| Health Services Accessibility | 3 | 2022 | 901 | 0.290 |
Why?
| Risk Factors | 5 | 2025 | 9737 | 0.260 |
Why?
| Wisconsin | 3 | 2014 | 99 | 0.250 |
Why?
| Bayes Theorem | 2 | 2025 | 373 | 0.240 |
Why?
| Costs and Cost Analysis | 2 | 2025 | 200 | 0.230 |
Why?
| Spatio-Temporal Analysis | 1 | 2024 | 27 | 0.230 |
Why?
| Hospitals, Psychiatric | 1 | 2024 | 23 | 0.230 |
Why?
| Patient Acceptance of Health Care | 3 | 2023 | 757 | 0.230 |
Why?
| Aged | 7 | 2024 | 21974 | 0.230 |
Why?
| Health Policy | 3 | 2022 | 351 | 0.220 |
Why?
| Prisons | 1 | 2024 | 79 | 0.210 |
Why?
| Primary Health Care | 3 | 2023 | 1641 | 0.210 |
Why?
| Cities | 1 | 2023 | 105 | 0.200 |
Why?
| Life Expectancy | 1 | 2023 | 61 | 0.200 |
Why?
| Inpatients | 3 | 2022 | 468 | 0.200 |
Why?
| Quality-Adjusted Life Years | 2 | 2020 | 106 | 0.200 |
Why?
| Age Factors | 2 | 2020 | 3122 | 0.190 |
Why?
| International Cooperation | 1 | 2022 | 173 | 0.190 |
Why?
| Immunogenicity, Vaccine | 1 | 2022 | 27 | 0.190 |
Why?
| Arkansas | 1 | 2021 | 15 | 0.190 |
Why?
| Ambulances | 1 | 2022 | 50 | 0.190 |
Why?
| Colorectal Neoplasms | 1 | 2009 | 751 | 0.190 |
Why?
| Models, Economic | 1 | 2021 | 53 | 0.190 |
Why?
| Needle Sharing | 1 | 2021 | 10 | 0.180 |
Why?
| Delphi Technique | 1 | 2022 | 222 | 0.180 |
Why?
| Markov Chains | 1 | 2021 | 116 | 0.180 |
Why?
| Quality of Life | 3 | 2022 | 2688 | 0.180 |
Why?
| Evidence-Based Practice | 4 | 2025 | 208 | 0.180 |
Why?
| Prescriptions | 1 | 2021 | 65 | 0.180 |
Why?
| Interrupted Time Series Analysis | 1 | 2021 | 53 | 0.180 |
Why?
| Health Services | 1 | 2021 | 97 | 0.180 |
Why?
| Homosexuality, Male | 1 | 2022 | 175 | 0.180 |
Why?
| Betacoronavirus | 2 | 2020 | 247 | 0.180 |
Why?
| Drug Resistance, Viral | 2 | 2022 | 110 | 0.180 |
Why?
| Drug Compounding | 1 | 2021 | 96 | 0.170 |
Why?
| Catheterization, Central Venous | 1 | 2022 | 103 | 0.170 |
Why?
| Intersectoral Collaboration | 1 | 2020 | 60 | 0.170 |
Why?
| Sex Factors | 2 | 2020 | 1951 | 0.170 |
Why?
| Prescription Drugs | 1 | 2021 | 112 | 0.170 |
Why?
| Social Isolation | 1 | 2020 | 60 | 0.170 |
Why?
| Communicable Disease Control | 1 | 2020 | 73 | 0.170 |
Why?
| Patient Advocacy | 1 | 2020 | 73 | 0.170 |
Why?
| Demography | 1 | 2020 | 278 | 0.170 |
Why?
| Clinical Laboratory Techniques | 1 | 2020 | 93 | 0.160 |
Why?
| Public Health Administration | 1 | 2020 | 75 | 0.160 |
Why?
| Russia | 1 | 2019 | 11 | 0.160 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2022 | 177 | 0.160 |
Why?
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 17 | 0.160 |
Why?
| New York | 3 | 2025 | 125 | 0.160 |
Why?
| Age Distribution | 2 | 2018 | 373 | 0.160 |
Why?
| Sex Distribution | 2 | 2018 | 358 | 0.160 |
Why?
| Health Status | 1 | 2024 | 747 | 0.160 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2024 | 1358 | 0.150 |
Why?
| Narcotics | 1 | 2018 | 45 | 0.150 |
Why?
| Medicaid | 1 | 2022 | 433 | 0.150 |
Why?
| Needs Assessment | 1 | 2020 | 356 | 0.150 |
Why?
| Urban Population | 1 | 2021 | 441 | 0.140 |
Why?
| Surgeons | 1 | 2022 | 259 | 0.140 |
Why?
| Uridine Monophosphate | 1 | 2017 | 15 | 0.140 |
Why?
| Child | 5 | 2021 | 20805 | 0.140 |
Why?
| Proportional Hazards Models | 1 | 2020 | 1200 | 0.140 |
Why?
| Fluorenes | 1 | 2017 | 40 | 0.140 |
Why?
| Disease Management | 1 | 2021 | 584 | 0.130 |
Why?
| Sofosbuvir | 1 | 2017 | 58 | 0.130 |
Why?
| Rural Population | 1 | 2021 | 517 | 0.130 |
Why?
| Mental Health Services | 1 | 2021 | 402 | 0.130 |
Why?
| Ribavirin | 1 | 2017 | 91 | 0.130 |
Why?
| Computer Simulation | 1 | 2021 | 939 | 0.130 |
Why?
| Benzimidazoles | 1 | 2017 | 160 | 0.130 |
Why?
| Physician-Patient Relations | 1 | 2020 | 530 | 0.130 |
Why?
| Obesity | 1 | 2009 | 2864 | 0.130 |
Why?
| Telemedicine | 1 | 2024 | 786 | 0.120 |
Why?
| Recurrence | 1 | 2018 | 1004 | 0.120 |
Why?
| Midwestern United States | 1 | 2015 | 41 | 0.120 |
Why?
| Skin | 1 | 2020 | 717 | 0.120 |
Why?
| Multivariate Analysis | 1 | 2019 | 1499 | 0.120 |
Why?
| Vaccination | 2 | 2020 | 1346 | 0.120 |
Why?
| Viral Load | 1 | 2017 | 449 | 0.120 |
Why?
| Incidence | 2 | 2020 | 2638 | 0.120 |
Why?
| Health Promotion | 1 | 2021 | 716 | 0.120 |
Why?
| Surveys and Questionnaires | 4 | 2015 | 5371 | 0.110 |
Why?
| Amphotericin B | 1 | 2014 | 29 | 0.110 |
Why?
| Drug Therapy, Combination | 1 | 2017 | 1016 | 0.110 |
Why?
| Kentucky | 2 | 2025 | 39 | 0.110 |
Why?
| Severity of Illness Index | 2 | 2020 | 2719 | 0.110 |
Why?
| Epidemiologic Methods | 1 | 2014 | 74 | 0.110 |
Why?
| RNA, Viral | 1 | 2017 | 615 | 0.110 |
Why?
| Antifungal Agents | 1 | 2014 | 128 | 0.110 |
Why?
| Early Diagnosis | 1 | 2014 | 234 | 0.100 |
Why?
| Professional-Patient Relations | 1 | 2014 | 139 | 0.100 |
Why?
| Social Stigma | 1 | 2014 | 117 | 0.100 |
Why?
| Genotype | 1 | 2017 | 1830 | 0.100 |
Why?
| Patient Education as Topic | 2 | 2024 | 734 | 0.100 |
Why?
| Anti-Bacterial Agents | 1 | 2022 | 1705 | 0.090 |
Why?
| Methadone | 2 | 2024 | 89 | 0.090 |
Why?
| Physicians, Primary Care | 1 | 2014 | 226 | 0.090 |
Why?
| Advance Care Planning | 1 | 2014 | 203 | 0.090 |
Why?
| Physicians | 1 | 2020 | 863 | 0.090 |
Why?
| North America | 2 | 2023 | 290 | 0.090 |
Why?
| Internal Medicine | 1 | 2013 | 246 | 0.090 |
Why?
| Fear | 1 | 2014 | 347 | 0.090 |
Why?
| Pregnancy, High-Risk | 1 | 2010 | 15 | 0.090 |
Why?
| Recreation Therapy | 1 | 2010 | 5 | 0.090 |
Why?
| Bed Rest | 1 | 2010 | 14 | 0.080 |
Why?
| Music Therapy | 1 | 2010 | 22 | 0.080 |
Why?
| Infant, Newborn | 1 | 2021 | 5740 | 0.080 |
Why?
| Decision Making | 1 | 2016 | 847 | 0.080 |
Why?
| Education, Medical, Graduate | 1 | 2013 | 435 | 0.080 |
Why?
| Chronic Disease | 1 | 2014 | 1692 | 0.080 |
Why?
| Internship and Residency | 2 | 2014 | 1045 | 0.070 |
Why?
| Attitude of Health Personnel | 1 | 2014 | 1090 | 0.070 |
Why?
| Counseling | 1 | 2009 | 384 | 0.060 |
Why?
| Anorexia | 1 | 2005 | 18 | 0.060 |
Why?
| Los Angeles | 1 | 2025 | 63 | 0.060 |
Why?
| Pregnancy Complications | 1 | 2010 | 491 | 0.060 |
Why?
| Cachexia | 1 | 2005 | 60 | 0.060 |
Why?
| Recovery of Function | 1 | 2008 | 633 | 0.060 |
Why?
| Community Participation | 1 | 2025 | 123 | 0.060 |
Why?
| Government | 1 | 2022 | 12 | 0.050 |
Why?
| Healthcare Disparities | 1 | 2009 | 579 | 0.050 |
Why?
| Treatment Outcome | 1 | 2017 | 10162 | 0.050 |
Why?
| Organizations | 1 | 2022 | 22 | 0.050 |
Why?
| Neoplasms | 2 | 2008 | 2463 | 0.050 |
Why?
| Public Opinion | 1 | 2022 | 63 | 0.050 |
Why?
| Syringes | 1 | 2022 | 41 | 0.050 |
Why?
| Oregon | 1 | 2021 | 70 | 0.050 |
Why?
| Immunization, Secondary | 1 | 2022 | 87 | 0.050 |
Why?
| Stress, Psychological | 1 | 2010 | 1064 | 0.050 |
Why?
| Vaccines, Synthetic | 1 | 2022 | 126 | 0.050 |
Why?
| Public Health Practice | 1 | 2022 | 64 | 0.050 |
Why?
| British Columbia | 1 | 2020 | 14 | 0.040 |
Why?
| Infectious Disease Medicine | 1 | 2020 | 12 | 0.040 |
Why?
| Invasive Fungal Infections | 1 | 2020 | 10 | 0.040 |
Why?
| Federal Government | 1 | 2020 | 27 | 0.040 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 1276 | 0.040 |
Why?
| Human Rights | 1 | 2020 | 18 | 0.040 |
Why?
| Health Care Rationing | 1 | 2020 | 57 | 0.040 |
Why?
| State Government | 1 | 2020 | 43 | 0.040 |
Why?
| Delayed-Action Preparations | 1 | 2021 | 170 | 0.040 |
Why?
| Canada | 1 | 2021 | 346 | 0.040 |
Why?
| Hepatitis B | 1 | 2020 | 63 | 0.040 |
Why?
| Comparative Effectiveness Research | 1 | 2020 | 146 | 0.040 |
Why?
| Health Education | 1 | 2022 | 332 | 0.040 |
Why?
| Infection Control | 1 | 2020 | 138 | 0.040 |
Why?
| Specialization | 1 | 2020 | 144 | 0.040 |
Why?
| Bacteremia | 1 | 2020 | 197 | 0.040 |
Why?
| Regression Analysis | 1 | 2020 | 982 | 0.040 |
Why?
| Patient Compliance | 1 | 2022 | 560 | 0.040 |
Why?
| Communication | 1 | 2022 | 841 | 0.030 |
Why?
| Societies, Medical | 1 | 2020 | 744 | 0.030 |
Why?
| Leadership | 1 | 2020 | 352 | 0.030 |
Why?
| Prospective Studies | 2 | 2023 | 7069 | 0.030 |
Why?
| Databases, Factual | 1 | 2020 | 1267 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2022 | 1357 | 0.030 |
Why?
| Patient Readmission | 1 | 2020 | 665 | 0.030 |
Why?
| Behavior Therapy | 1 | 2014 | 236 | 0.020 |
Why?
| Focus Groups | 1 | 2013 | 452 | 0.020 |
Why?
| Watchful Waiting | 1 | 2010 | 65 | 0.020 |
Why?
| Qualitative Research | 1 | 2013 | 1227 | 0.020 |
Why?
| Sickness Impact Profile | 1 | 2005 | 55 | 0.020 |
Why?
| Psychometrics | 1 | 2005 | 682 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2008 | 3021 | 0.010 |
Why?
| Pregnancy | 1 | 2010 | 6373 | 0.010 |
Why?
| Prognosis | 1 | 2005 | 3780 | 0.010 |
Why?
| Risk Assessment | 1 | 2005 | 3232 | 0.010 |
Why?
|
|
Barocas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|